Showing 2101-2110 of 6043 results for "".
Physician Spotlight: Steven R. Feldman, MD, PhD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-4/23801/DEI in Dermatology
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/dei-in-dermatology/20143/Dermatology remains one of the least diverse medical specialties, says Jeanine Downie, MD. There have been small steps forward to improve diversity, equity, inclusion, and accessibility in recent years, such as the DREAM initiative from Allergan Aesthetics and skinbetter science. But there is stillRecent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-37/23755/New Products
https://practicaldermatology.com/columns/new-products/new-products-4/23753/The Current Armamentarium of Topical Therapies to Treat Atopic Dermatitis and Psoriasis
https://practicaldermatology.com/topics/atopic-dermatitis/the-current-armamentarium-of-topical-therapies-to-treat-atopic-dermatitis-and-psoriasis/23748/A review of the alternatives to topical corticosteroids for managing common inflammatory skin diseases.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-36/23740/DermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyAncillary Services and Alternative Revenue Streams for Dermatologists
https://practicaldermatology.com/topics/practice-management/ancillary-services-and-alternative-revenue-streams-for-dermatologists/23535/Dermatologists have many opportunities to use their skills beyond patient care.DermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improvesConjunctival Squamous Cell Carcinoma: A Video-Illustration of a Surgical Approach
https://practicaldermatology.com/youngmd-connect/resident-resource-center/conjunctival-squamous-cell-carcinoma-a-video-illustration-of-a-surgical-approach/23378/